In this session, Sir Michael Brady will discuss how quantitative MRI (qMRI) is transforming radiology from qualitative image interpretation to quantified biomarker assessment. By delivering images with physical dimensions like T2 relaxation times, qMRI reduces variability between reporters. qMRI can then be applied to map aspects of metabolic syndrome, from NAFLD/NASH to the biliary tree, and to guide liver cancer treatment decisions. Multi-organ qMRI mapping has also furthered understanding of type 2 diabetes and long Covid. This talk will highlight the development of AI-based clinical decision support tools that integrate qMRI biomarkers with Bayesian networks to assist clinicians treating metabolic diseases.